MXPA02004793A - Derivados de isoindolina farmaceuticamente activos. - Google Patents
Derivados de isoindolina farmaceuticamente activos.Info
- Publication number
- MXPA02004793A MXPA02004793A MXPA02004793A MXPA02004793A MXPA02004793A MX PA02004793 A MXPA02004793 A MX PA02004793A MX PA02004793 A MXPA02004793 A MX PA02004793A MX PA02004793 A MXPA02004793 A MX PA02004793A MX PA02004793 A MXPA02004793 A MX PA02004793A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically active
- isoindoline derivatives
- active isoindoline
- derivatives
- oxoisoindoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16516899P | 1999-11-12 | 1999-11-12 | |
US59034400A | 2000-06-08 | 2000-06-08 | |
US09/708,199 US6667316B1 (en) | 1999-11-12 | 2000-11-08 | Pharmaceutically active isoindoline derivatives |
PCT/US2000/030770 WO2001034606A1 (en) | 1999-11-12 | 2000-11-09 | Pharmaceutically active isoindoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02004793A true MXPA02004793A (es) | 2003-10-14 |
Family
ID=27389110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02004793A MXPA02004793A (es) | 1999-11-12 | 2000-11-09 | Derivados de isoindolina farmaceuticamente activos. |
Country Status (19)
Country | Link |
---|---|
US (1) | US6667316B1 (es) |
EP (4) | EP1228071B8 (es) |
JP (1) | JP5116201B2 (es) |
CN (1) | CN1325497C (es) |
AT (4) | ATE544452T1 (es) |
AU (2) | AU782409B2 (es) |
CA (1) | CA2392081C (es) |
CY (2) | CY1107610T1 (es) |
DE (1) | DE60034139T2 (es) |
DK (2) | DK1228071T3 (es) |
ES (4) | ES2381174T3 (es) |
FI (1) | FI119931B (es) |
HK (2) | HK1049158A1 (es) |
MX (1) | MXPA02004793A (es) |
NO (2) | NO323633B1 (es) |
NZ (1) | NZ519459A (es) |
PT (2) | PT2263669E (es) |
SI (1) | SI1228071T1 (es) |
WO (1) | WO2001034606A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
ES2315435T3 (es) * | 1996-08-12 | 2009-04-01 | Celgene Corporation | Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas. |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
AU2002257195A1 (en) | 2001-04-23 | 2002-11-05 | University Of Virginia Patent Foundation | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
DE60231989D1 (de) * | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
AU2003234624B8 (en) | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
KR20050056247A (ko) | 2002-10-15 | 2005-06-14 | 셀진 코포레이션 | 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물 |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
MXPA05004486A (es) * | 2002-10-31 | 2005-07-26 | Celgene Corp | Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular. |
NZ540384A (en) * | 2002-11-06 | 2008-06-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2505131A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20040167199A1 (en) * | 2002-11-18 | 2004-08-26 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
DE60330187D1 (de) | 2002-12-30 | 2009-12-31 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
EP1605935A4 (en) * | 2003-03-06 | 2009-05-20 | Celgene Corp | METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
AU2004220456B2 (en) * | 2003-03-12 | 2010-10-14 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
CA2518584A1 (en) | 2003-03-12 | 2004-09-23 | Celgene Corporation | 7-amino- isoindolyl compounds and their pharmaceutical uses |
EP1613269B1 (en) | 2003-04-04 | 2015-02-25 | Incyte Corporation | Compositions, methods and kits relating to her-2 cleavage |
US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
JP2007524656A (ja) * | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
EP1744748A4 (en) * | 2004-04-14 | 2009-08-12 | Celgene Corp | METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES |
CN1972684A (zh) * | 2004-04-23 | 2007-05-30 | 细胞基因公司 | 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法 |
EP1750697A4 (en) * | 2004-05-05 | 2009-08-26 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITION DRUGS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
US20090010886A1 (en) * | 2004-05-05 | 2009-01-08 | Celgene Corporation | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione |
WO2006004191A1 (en) * | 2004-07-05 | 2006-01-12 | Astellas Pharma Inc. | Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa |
US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
CN101052630A (zh) | 2004-09-03 | 2007-10-10 | 细胞基因公司 | 取代的杂环化合物和其用途 |
WO2006050057A2 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
KR20070092276A (ko) * | 2004-12-13 | 2007-09-12 | 셀진 코포레이션 | Pde4 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
CN102036663A (zh) * | 2008-03-24 | 2011-04-27 | 细胞基因公司 | 用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎 |
US8563580B2 (en) * | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
US9040715B2 (en) | 2008-09-23 | 2015-05-26 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
PE20120580A1 (es) | 2009-02-10 | 2012-05-23 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
CN107964016B (zh) * | 2009-05-14 | 2021-10-01 | 天津合美医药科技有限公司 | 噻吩衍生物 |
ME01883B (me) | 2009-06-18 | 2014-12-20 | Concert Pharmaceuticals Inc | Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa |
CN102639498A (zh) * | 2009-10-09 | 2012-08-15 | 细胞基因公司 | 制备2-(1-苯乙基)异吲哚啉-1-酮化合物的方法 |
RU2012131164A (ru) * | 2009-12-22 | 2014-01-27 | Селджин Корпорейшн | (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
JP2013531499A (ja) | 2010-06-15 | 2013-08-08 | セルジーン コーポレイション | 乾癬の治療のためのバイオマーカー |
JP6132773B2 (ja) * | 2011-01-10 | 2017-05-24 | セルジーン コーポレイション | Pde4及び/又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体 |
MX2013007959A (es) | 2011-01-10 | 2013-12-06 | Celgene Corp | Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico. |
WO2012097116A2 (en) | 2011-01-14 | 2012-07-19 | Celgene Corporation | Isotopologues of isoindole derivatives |
ES2868231T3 (es) | 2011-03-07 | 2021-10-21 | Amgen Europe Gmbh | Métodos de tratamiento de enfermedades usando compuestos de isoindolina |
AU2012296543B2 (en) | 2011-08-16 | 2016-08-11 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
ES2803524T3 (es) * | 2011-09-14 | 2021-01-27 | Amgen Europe Gmbh | Formulaciones de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida del ácido ciclopropanocarboxílico |
US8981117B2 (en) | 2012-09-14 | 2015-03-17 | Celgene Corporation | Processes for the preparation of isoindole compounds and isotopologues thereof |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
JP6687550B2 (ja) | 2014-06-23 | 2020-04-22 | セルジーン コーポレイション | 肝疾患又は肝機能異常を治療するためのアプレミラスト |
US10287248B2 (en) * | 2015-03-19 | 2019-05-14 | Cipla Limited | Process for the preparation of apremilast |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
HU231259B1 (hu) | 2016-02-04 | 2022-06-28 | Egyt Gyogyszervegyeszeti Gyar | Eljárás pomalidomide elõállítására |
AU2017317123B9 (en) * | 2016-08-22 | 2021-11-25 | Medshine Discovery Inc. | PDE4 inhibitor |
CN107698484B (zh) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | 一种来那度胺的衍生物的制备方法与应用 |
WO2019142124A1 (en) | 2018-01-17 | 2019-07-25 | Cadila Healthcare Limited | Pharmaceutical compositions for treatment of vitiligo |
AU2019254962C1 (en) | 2018-04-17 | 2023-04-27 | Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd | Isoindole derivatives |
WO2020020101A1 (zh) * | 2018-07-22 | 2020-01-30 | 上海星叶医药科技有限公司 | 苯并异硒唑酮胺类化合物及其制备方法和用途 |
CN110003084B (zh) * | 2019-03-15 | 2022-08-02 | 华南师范大学 | 一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用 |
CN111170925B (zh) * | 2020-01-09 | 2023-01-17 | 常州大学 | 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法 |
CN117203196A (zh) * | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
CN114790164B (zh) | 2021-08-13 | 2022-12-27 | 苏州璞正医药有限公司 | 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
SE434638B (sv) | 1980-06-06 | 1984-08-06 | Lekemedelsfabriken Medica Ab | Nya terapeutiska verdefulla taurinderivat och deras framstellning |
US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
JP3131225B2 (ja) | 1995-07-26 | 2001-01-31 | ファイザー・インコーポレーテッド | N−(アロイル)グリシンヒドロキサム酸誘導体および関連化合物 |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
WO1997024117A1 (en) | 1996-01-02 | 1997-07-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
CA2263154A1 (en) * | 1996-08-07 | 1998-02-12 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
ES2315435T3 (es) | 1996-08-12 | 2009-04-01 | Celgene Corporation | Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas. |
CZ299873B6 (cs) * | 1997-07-31 | 2008-12-17 | Celgene Corporation | Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
-
2000
- 2000-11-08 US US09/708,199 patent/US6667316B1/en not_active Expired - Lifetime
- 2000-11-09 AT AT10176420T patent/ATE544452T1/de active
- 2000-11-09 WO PCT/US2000/030770 patent/WO2001034606A1/en active IP Right Grant
- 2000-11-09 SI SI200030951T patent/SI1228071T1/sl unknown
- 2000-11-09 CA CA002392081A patent/CA2392081C/en not_active Expired - Fee Related
- 2000-11-09 AU AU14780/01A patent/AU782409B2/en not_active Ceased
- 2000-11-09 ES ES10176390T patent/ES2381174T3/es not_active Expired - Lifetime
- 2000-11-09 DE DE60034139T patent/DE60034139T2/de not_active Expired - Lifetime
- 2000-11-09 AT AT00977095T patent/ATE357913T1/de active
- 2000-11-09 NZ NZ519459A patent/NZ519459A/en not_active IP Right Cessation
- 2000-11-09 DK DK00977095T patent/DK1228071T3/da active
- 2000-11-09 MX MXPA02004793A patent/MXPA02004793A/es active IP Right Grant
- 2000-11-09 EP EP00977095A patent/EP1228071B8/en not_active Expired - Lifetime
- 2000-11-09 JP JP2001536553A patent/JP5116201B2/ja not_active Expired - Fee Related
- 2000-11-09 CN CNB00818254XA patent/CN1325497C/zh not_active Expired - Fee Related
- 2000-11-09 AT AT10176390T patent/ATE544451T1/de active
- 2000-11-09 AT AT06009632T patent/ATE506058T1/de not_active IP Right Cessation
- 2000-11-09 EP EP10176420A patent/EP2263669B1/en not_active Expired - Lifetime
- 2000-11-09 EP EP10176390A patent/EP2255801B1/en not_active Expired - Lifetime
- 2000-11-09 EP EP06009632A patent/EP1698334B1/en not_active Expired - Lifetime
- 2000-11-09 PT PT10176420T patent/PT2263669E/pt unknown
- 2000-11-09 PT PT00977095T patent/PT1228071E/pt unknown
- 2000-11-09 ES ES10176420T patent/ES2380574T3/es not_active Expired - Lifetime
- 2000-11-09 DK DK10176420.7T patent/DK2263669T3/da active
- 2000-11-09 ES ES00977095T patent/ES2282147T3/es not_active Expired - Lifetime
- 2000-11-09 ES ES06009632T patent/ES2363933T3/es not_active Expired - Lifetime
-
2002
- 2002-05-08 NO NO20022223A patent/NO323633B1/no not_active IP Right Cessation
- 2002-05-10 FI FI20020892A patent/FI119931B/fi not_active IP Right Cessation
-
2003
- 2003-02-05 HK HK03100819.6A patent/HK1049158A1/zh unknown
- 2003-07-30 HK HK03105496A patent/HK1053467A1/xx not_active IP Right Cessation
-
2005
- 2005-07-07 AU AU2005202964A patent/AU2005202964B2/en not_active Ceased
-
2007
- 2007-03-21 NO NO20071490A patent/NO336210B1/no not_active IP Right Cessation
- 2007-04-05 CY CY20071100487T patent/CY1107610T1/el unknown
-
2012
- 2012-04-26 CY CY20121100399T patent/CY1112707T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1053467A1 (en) | Pharmaceutically active isoindoline derivatives | |
ATE317845T1 (de) | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate | |
ZA200201509B (en) | Pharmaceutically active sulfonamide derivatives. | |
NO20002217L (no) | Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
EP2767291A3 (en) | Treatment of glycogen storage disease type II | |
HK1045113A1 (zh) | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 | |
EP1295611A4 (en) | COMPOUNDS FOR THE TRANSFER OF OLIGONUCLEOTIDES (03.01.02) | |
IL142581A (en) | Medicament for treating heart disease | |
ZA9811154B (en) | (E)-3-(1-n-butyl-5-(2-(2-carboxyphenyl)methoxy-4-chlorophenyl)-1H-pyrazol-4-yl)-2-((5-methoxy-2,3-dihydrobenzo-furan-6-yl)methyl)-prop-2-enoic acid monoarginilyn salt | |
SE9902742D0 (sv) | New pharmaceutical formultion | |
AU7568500A (en) | Laser probe for medical treatment | |
AU6290398A (en) | Inclusion complexes in aqueous solution | |
ITMO990002A0 (it) | Articolatore per odontotecnica. | |
WO2002024210A3 (en) | Halogen compounds for use in medicine | |
SI1086695T1 (en) | Antiviral compositions comprising yohimbine as active principle | |
EE04951B1 (et) | R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks | |
EP1210949A4 (en) | Anti-ulcer agents | |
RU98106825A (ru) | Средство для лечения герпетических заболеваний глаз | |
IT1311630B1 (it) | Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'. | |
ZA200005185B (en) | Indole-2,3-Dione-3-Oxime derivatives for therapeutic use. | |
ES1042703Y (es) | "cuadro perfeccionado". | |
RU2001111898A (ru) | Способ повышения воспроизводительной способности хряков |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |